Pradyumna Tummala, MD
Interventional Cardiology · Atlanta, GANPI 1427000959
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.3%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 13.4%. 2025 is the largest year on record at $16,541, 4.3 times the $3,882 reported in 2019.
Across 442 payments — averaging $89.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$5K
- Medtronic$5K
- Heartflow, Inc.$5K
- Lantheus Medical Imaging, Inc.$3K
- Abbott$3K
- Edwards Lifesciences$3K
- plus $15K from 42 others
Across 12 payments — averaging $1674.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shockwave Medical, Inc$17K
- Medtronic$2K
- Cardiovascular Systems Inc.$1K
- Abiomed$59
Across 5 payments — averaging $20,600 each. An ownership or investment interest held by the physician or an immediate family member.
- Centerline Biomedical Inc.$103K
What the payments were for
- Consulting fees$1,5504%
- Speaking & faculty fees$7,68519%
- Travel & lodging$8,77922%
- Food & beverage$21,44154%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$4,529
- Definity$3,285
- GENERAL - THERAPIES$1,941
- CoreValve Evolut$1,181
- AccuCinch$1,147
- SYMPLICITY G3$1,127
- Impella$1,103
- GUIDEZILLA$800
- Coronary Orbital Atherectomy System$726
- Navicross$685
- Glidesheath$685
- GlideWire$685
- TRICLIP$654
- (9525) Intracardiac Und$566
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$551
- Orsiro Mission$510
- ONYX FRONTIER$503
- MitraClip$457
- GENERAL VASCULAR ACCESS$400
- FLOWTRIEVER CATHETER, S$367
How this compares
$39,454 in reported general payments places this provider in the 80th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 205 | $214,492 |
| Repatha SureclickEvolocumab | 170 | $184,540 |
| XareltoRivaroxaban | 103 | $108,569 |
| OzempicSemaglutide | 43 | $54,565 |
| Repatha SyringeEvolocumab | 27 | $27,342 |
| FarxigaDapagliflozin Propanediol | 18 | $25,829 |
| Praluent PenAlirocumab | 31 | $23,527 |
| EntrestoSacubitril/Valsartan | 15 | $18,378 |
| VascepaIcosapent Ethyl | 18 | $12,136 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $7,878 |
| Ezetimibe | 342 | $7,184 |
| Eplerenone | 49 | $3,914 |
| Metoprolol Succinate | 253 | $3,774 |
| Rosuvastatin Calcium | 363 | $3,436 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 65 | $2,531 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $501 | $214,492205 claims |
| Johnson & JohnsonXarelto | $408 | $108,569103 claims |
| Novo NordiskOzempic | $419 | $54,56543 claims |
| AstraZenecaFarxiga | $489 | $25,82918 claims |
| NovartisEntresto | $920 | $18,37815 claims |
| Esperion Therapeutics, Inc.Nexlizet | $254 | $7,87812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 218 interventional cardiology providers in Georgia.
Other interventional cardiology in Atlanta
- William NicholsonAtlanta$1000K
- David KandzariAtlanta$982K
- Pradeep YadavAtlanta$656K
- Adam GreenbaumAtlanta$238K
- Wissam JaberAtlanta$222K
- Katherine KunkelAtlanta$189K
- James StewartAtlanta$174K
- Pratik SandesaraAtlanta$165K
- Chandanreddy DevireddyAtlanta$121K
- Prashant KaulAtlanta$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.